Apolipoprotein B-containing lipoproteins: distinct roles in atherosclerosis revealed by plasma proteomic profiling
Journal article, 2026

Background and Aims All apolipoprotein B-containing lipoproteins are established causal factors for coronary artery disease (CAD). We aimed to identify robust proteomic signatures of LDL, triglyceride-rich lipoproteins (TRL), and lipoprotein(a) [Lp(a)] and to evaluate whether these signatures illuminate biological processes underlying differences in per-particle atherogenicity. Methods We identified plasma proteins associated with LDL, TRL, and Lp(a) concentrations using multivariable-adjusted regression across 2918 proteins in a primary prevention cohort based on UK Biobank (n = 35 269) and corroborated findings using one-sample Mendelian randomization. Proteins consistently identified by both approaches were summarized into lipoprotein-specific multi-protein scores and associated with incident CAD (n = 1599 events) using Cox regression. High-dimensional mediation analysis quantified the proportion of lipoprotein-associated CAD risk explained by proteomic alterations. Findings were replicated in the Multi-Ethnic Study of Atherosclerosis (n = 5915). Results Requiring concordance between observational and Mendelian randomization analyses (both Bonferroni-adjusted P < .05), we identified 30 proteins associated with LDL, 471 with TRL, and 53 with Lp(a). The TRL and Lp(a) signatures were distinct from the LDL signature yet overlapped substantially with each other (36 shared proteins), with common enrichment in inflammatory pathways. After adjustment for potential confounders and measured lipoprotein concentrations, the multi-protein scores for TRL [hazard ratio (HR) per 1-SD increase 1.16, 95% confidence interval (95% CI): 1.08-1.24] and Lp(a) (HR 1.09, 95% CI: 1.03-1.15), but not LDL (HR 0.95, 95% CI: 0.89-1.02), were associated with incident CAD. Mediation analysis was consistent with immune activation and vascular remodelling markers mediating TRL-associated CAD risk (proportion mediated, 62%) and, in part, Lp(a)-associated risk (14%). Conclusions Beyond arterial lipid deposition, TRL and Lp(a) converge on inflammatory and vascular remodelling pathways, which, under the assumptions of observational mediation analysis, may explain their excess per-particle atherogenicity compared with LDL.

Coronary artery disease

Proteomics

Apolipoprotein B-containing lipoproteins

Author

Jakub Morze

University of Gothenburg

Sahlgrenska University Hospital

Chalmers, Life Sciences, Food and Nutrition Science

Elias Bjornson

University of Gothenburg

Michael Y. Mi

Harvard Medical School

Martin Adiels

Mathematics

University of Gothenburg

Giorgio E. M. Melloni

Harvard Medical School

Goncalo R. da Silva

AstraZeneca AB

Andrzej Rynkiewicz

The Metropolitan Hospital of Nicolaus Copernicus

Nicholas A. Marston

Harvard Medical School

Marta Guasch-Ferre

Harvard University

University of Copenhagen

Michael Y. Tsai

University of Minnesota

Jerome I. Rotter

University of California

Robert E. Gerszten

Harvard Medical School

Qi Sun

Harvard University

Frank B. Hu

Harvard University

Rikard Landberg

University of Gothenburg

Chalmers, Life Sciences, Food and Nutrition Science

Goran Bergstrom

University of Gothenburg

Chris J. Packard

University of Glasgow

Jan Boren

University of Gothenburg

Clemens Wittenbecher

Chalmers, Life Sciences, Food and Nutrition Science

European Heart Journal

0195-668X (ISSN) 1522-9645 (eISSN)

Vol. In Press

The metabolomics imprint of controlled modification of carbohydrate quality elucidates long-term impact on cardiometabolic disease risk and facilitates precision prevention approaches

Swedish Research Council (VR) (2022-01529), 2023-01-01 -- 2026-12-31.

Subject Categories (SSIF 2025)

Cardiology and Cardiovascular Disease

DOI

10.1093/eurheartj/ehag718

PubMed

42671122

Related datasets

Supplementary data [dataset]

URI: https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehag718/2/ehag718_supplementary_data.zip?Expires=1795381743&Signature=ULLLfG9pgmYX2RMwWqz7PNH60D3XTVmD0pyPMZyLiHmJWOu6LSVjCLckdVP6iEUoQrfzyycQ4kVGc-n5l-DP5Mm0r10XjebyK0uGxY5u~uc8J0Pa4Bm6GN7NKzyi8N4eCvzKOPpPrCSPPoq3PJGrsFujhJi7m1w5TXMYr2V2qBNkzcT9wuu5juHs4FyF1Z8KY6S7lQKL2~zb6yQxp1JbHv6dqBmU6c2d-NqK5y5RjX0rM34G2OI~NWbBt5pOeabKU-NcxdKRphmtiXj7tWXuHCq6DyEk6gvmhOZz3haa-e8PI8DMPuDYe8Cx-HkjlEcWUW-XT7afNwXSgv3hNVuaZg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA

More information

Latest update

10/21/2026